Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
OpenAI in talks with Samsung to power AI features, report says
-
4
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
S. Korea not to attend Sado mine memorial: foreign ministry
-
8
South Korean military plans to launch new division for future warfare
-
9
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
10
North Korean leader ‘convinced’ dialogue won’t change US hostility
[THE INVESTOR] The National Pension Service has decided to file a compensation suit against Hanmi Pharmaceutical should its alleged wrongdoings be proven true.
Speaking at the parliamentary audit, NPS’s Chief Investment Officer Kang Myeon-wook said that the agency will seek compensation if it is proven that Hanmi’s irregular dealings led to any losses for it.
Hanmi is alleged to have delayed in disclosing the fact that its contract with Boehringer Ingelheim has been terminated. Following the disclosure, the company’s shares fell from 620,000 won (US$ 559.10) on Sept. 29 to 457,000 won on Oct. 5, causing estimated loss of 150 billion won for the NPS.
It has also been alleged that information that would bring its shares down was circulated on mobile messenger services ahead of the disclosure. The company has since come under the scrutiny of financial authorities. Hanmi Pharmaceutical closed at 435,000 won, up 2.84 percent, on Oct. 10.
By Choi He-suk (cheesuk@heraldcorp.com)
Speaking at the parliamentary audit, NPS’s Chief Investment Officer Kang Myeon-wook said that the agency will seek compensation if it is proven that Hanmi’s irregular dealings led to any losses for it.
Hanmi is alleged to have delayed in disclosing the fact that its contract with Boehringer Ingelheim has been terminated. Following the disclosure, the company’s shares fell from 620,000 won (US$ 559.10) on Sept. 29 to 457,000 won on Oct. 5, causing estimated loss of 150 billion won for the NPS.
It has also been alleged that information that would bring its shares down was circulated on mobile messenger services ahead of the disclosure. The company has since come under the scrutiny of financial authorities. Hanmi Pharmaceutical closed at 435,000 won, up 2.84 percent, on Oct. 10.
By Choi He-suk (cheesuk@heraldcorp.com)
